Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Leukemia 3 Myelodysplastic Syndromes 2 Leukemia, Myelomonocytic, Juvenile 2 Inflammation 2 Asthma 2 Wilms Tumor 1 Vasculitis 1 Uveitis 1 Temporomandibular Joint Disorders 1 Stomatitis 1 Spondylitis, Ankylosing 1 Respiratory Distress Syndrome 1 Recurrence 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neuroblastoma 1 Neoplasms 1 Myeloproliferative Disorders 1 Myelodysplastic-Myeloproliferative Diseases 1 Lupus Nephritis 1 Lung Injury 1 Leukemia, Myeloid, Chronic-Phase 1 Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1 Leukemia, Myeloid, Accelerated Phase 1 Immunoglobulin Light-chain Amyloidosis 1 Granulomatosis with Polyangiitis 1 Fatigue Syndrome, Chronic 1 Dendritic Cell Sarcoma, Interdigitating 1 Burkitt Lymphoma 1 Bronchiolitis Obliterans 1 Blast Crisis 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Lupus Nephritis × Etanercept × Clear all

NCT00447265 2013-02-12

Etanercept for the Treatment of Lupus Nephritis

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 2 Terminated

1 enrolled 15 charts

Lupus Nephritis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡